Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
21.16 15.81 15.75 14.03
Current Ratio
21.67 39.87 39.53 34.45
Net Debt/EBITDA
(2.86) (1.47) (0.89) (0.31)
Debt/Assets
43.09% 42.41% 41.67% 39.96%
Debt/Equity
0.79 0.77 0.74 0.70
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.08 0.32 0.86 0.78
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
(3.53) (4.52) (6.10) (9.50)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.68) (0.20) (1.06) (1.56)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.68) (0.20) (1.06) (1.56)
Cash per Share
10.31 11.01 11.44 11.83
Shareholders Equity per Share
15.83 16.32 17.08 17.82
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
15.83 16.32 17.08 17.82
Free Cash Flow
(4.64) (1.34) (7.08) (10.56)
Working Capital
68.30 183.58 186.59 190.57
Net Current Asset Value
(18.73) 98.57 101.77 104.92
Other line items
Average Payables
0.66 0.54 0.72 1.06
Average Assets
214.35 218.94 233.55 242.17
Average Common Equity
119.53 127.81 141.65 148.38

Fold the line items

Columns are period end dates